Dr. David J. Mazzo is the President and Chief Executive Officer at Lisata Therapeutics (previously Caladrius Biosciences).

Dr. Mazzo is a pharmaceutical executive and strategic leader with more than 35 years of broad international experience developing and launching drug products for both big pharma and emerging pharma in the U.S., Canada, Europe and Japan. He is also a seasoned board director, having served on the boards of all the companies for which he was CEO, as well as Essex Chemie AG (EU subsidiary of Schering-Plough), Avanir Pharmaceuticals and EyePoint Pharmaceuticals, where he served as chairman of the board until 2018. Dr. Mazzo is the current chairman of the board of Visioneering Technologies, Inc.

Dr. Mazzo earned a Ph.D. in Analytical Chemistry and an M.S. in Chemistry from the University of Massachusetts (Amherst), and he completed a research fellowship at the École Polytechnique Fédérale de Lausanne (Switzerland). He also holds a B.S. (Chemistry) and a B.A. (Honors – Interdisciplinary Humanities) from Villanova University (Pennsylvania).

Ms. Sandoval currently serves as a consultant to the pharmaceutical industry and is a member of the board of directors of Procept BioRobotics since October 2021 where she serves as a member of the nom-esg and compensation committees and Vyne Therapeutics, Inc., since March 2019, where she serves as chair of the compensation committee and member of the audit committee. Ms. Sandoval was previously a member of the board of directors of Satsuma Pharmaceuticals Inc. until its acquisition by Shin Nippon Biomedical Laboratories in June 2023 and Intersect ENT, Inc. until its acquisition by Medtronic plc in May 2022. Ms. Sandoval previously served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy at Alder Biopharmaceuticals, a public biopharmaceutical company, from August 2016 until March 2019. Prior to that, she was Chief Commercial Officer for Kythera Biopharmaceuticals, a public biopharmaceutical company, from March 2012 until October 2015 and spent over 20 years at Allergan in a variety of commercial leadership roles of increasing responsibility. Ms. Sandoval holds a B.S. in Biology from University of California at Irvine and an M.B.A. from Pepperdine University. 

Nathalie Chauret is Vice President, Early Phase Development at Bellus Health Inc where she directs the preclinical toxicology and clinical pharmacology programs of new products. 

Ms. Chauret has over 30 years of experience in drug discovery and drug development in the biopharmaceutical industry. Prior to joining Bellus Health, N. Chauret led DMPK, pharmaceutical sciences and phase 1 clinical activities with increasing responsibilities at Merck Frosst, Virochem Pharma and Vertex Pharmaceuticals. Throughout her career, she has been involved in the discovery and development of several marketed drugs in different therapeutic areas (asthma, pain, osteoporosis and cystic fibrosis). 

Ms. Chauret holds a Master’s degree in Chemistry from the Université of Montreal and has published over 50 research papers, abstracts and patents. 

Mr. Stiff joined Genesys Capital in 2002. During his tenure with Genesys, he has been responsible for investments in several early-stage portfolio companies that cross a multitude of clinical disciplines and technology areas. Current board affiliations include Giiant Pharma Inc., and Veralox Therapeutics, Inc. Past board affiliations include Allostera Pharma, EBT Medical, Fairhaven Pharmaceuticals (Acquired by Liminal BioSciences Inc. NASDAQ:LMNL), gIcare Pharma, Inversago Pharma (Acquired by Novo Nordisk) Interface Biologics, Matregen, Naurex (acquired by Allergan NYSE:AGN), NeurAxon, StemPath, Therapeutic Monitoring Systems and Zelos Therapeutics. Mr. Stiff also volunteers as a board member for BIOTECanada, and as an advisor to the Ontario Genomics Institute (OGI), the Centre for Commercialization of Regenerative Medicine (CCRM) and Medicine by Design and as an associate with the Creative Destruction Lab (CDL). 

Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics field. This experience, combined with an academic background in biology, has provided significant technical knowledge of many areas of life sciences. Mr. Stiff completed a Bachelor of Science (Honours) from Queen’s University and an MBA from the Rotman School of Management. 

Mr. Truex serves as CEO and Chairman for Thryv Therapeutics (Formerly LQT Therapeutics).

Before Thryv Therapeutics, Mr. Truex recently served as the Executive Chairman, Director, and Chief Executive Officer of Anthera Pharmaceuticals.

Mr. Truex has been involved in over $5 billion in biotech financing and strategic transactions. His recent experience includes initial public offerings for Milestone (Board Member, 2019), Trius (Board Member, 2010), Anthera (CEO, 2010), Peninsula (CEO, 2004), and Versicor (Vice President, 2000). Mr. Truex was Founder, President, and CEO of Peninsula Pharmaceuticals which was acquired by Johnson & Johnson and Forest for more than $700 million.

Mr. Truex began his biotech career at Eli Lilly where his business development experience included the Lilly ICOS joint venture for the development of Cialis®. Mr. Truex is a member of the Board of Milestone (MIST), Cymabay (CBAY), Anthera (ANTH), and Gladius.

Mr. Truex obtained his MBA from Indiana University and a BA in Economics from the University of Waterloo.